Research Updates on KN046 Presented at 2022 ASCO
yahoo.com
news
2022-06-06 01:47:00

SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that research updates from four clinical studies of KN046 (PD-L1/CTLA-4 bispecific antibody) presented as a poster or published online at the 2022 American Society of Clinical Oncology Annual Meeting (2022 ASCO).

01

Title: A Multicenter, Randomized, Double-Blind Phase III Clinical Study to Evaluate the Efficacy and Safety of KN046 Combined with Nab-Paclitaxel and Gemcitabine Versus Placebo Combined with Nab-Paclitaxel and Gemcitabine in Patients with Advanced Pancreatic Cancer (ENREACH-PDAC-01)

Abstract Number: TPS4189

Poster Number: 159b

Most patients with pancreatic cancer, one of the most aggressive malignancies, are diagnosed as locally advanced (unresectable) or metastatic disease.
